NCT04280965View on ClinicalTrials.gov

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

April 29, 2022

Study Completion Date

October 17, 2022

Conditions
Post Traumatic Stress Disorder
Interventions
DRUG

Quetiapine Fumarate

Atypical antipsychotic

OTHER

Standard of care meducations

SSRI's/SNRI's/Trazodone/Prazosin/Hydroxyzine

Trial Locations (1)

78229

UT Health San Antonio, San Antonio

All Listed Sponsors
collaborator

South Central MIRECC

UNKNOWN

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT04280965 - Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury | Biotech Hunter | Biotech Hunter